Identification of Metabolites for the Novel 5α-Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing

    November 2025 in “ Drug Testing and Analysis ”
    Zhongquan Li, Bing Liu, Yirang Wang … Peijie Chen
    Studysummary This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 10

    1. Emerging and Traditional 5-Alpha Reductase Inhibitors and Androgen Receptor Antagonists for Male Androgenetic Alopecia Expert opinion on emerging drugs · 2024
    2. 5α-Reductase Inhibitors: Evaluation of Their Potential Confounding Effect on GC-C-IRMS Doping Analysis Drug Testing and Analysis · 2021
    3. High-Resolution Mass Spectrometric Investigation of the Phase I and II Metabolites of Finasteride in Pig Plasma, Urine, and Bile Xenobiotica · 2013
    4. Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry Drug Metabolism and Disposition · 2009
    5. Discovery and Clinical Development of Dutasteride, a Potent Dual 5α-Reductase Inhibitor Current topics in medicinal chemistry · 2006
    6. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004
    7. Clinical Application of 5α-Reductase Inhibitors Journal of endocrinological investigation · 2001
    8. Finasteride, a Type 2 5α-Reductase Inhibitor, in the Treatment of Men with Androgenetic Alopecia Expert Opinion on Investigational Drugs · 1999
    9. In Vitro Biotransformation of Finasteride in Rat Hepatic Microsomes: Isolation and Characterization of Metabolites PubMed · 1994
    10. The Clinical Development of a 5α-Reductase Inhibitor, Finasteride The Journal of Steroid Biochemistry and Molecular Biology · 1990